text
"['\nIX. 계열회사 등에 관한 사항\n가. 계열회사 출자 현황\r\n(기준일: 2017년 12월 31일)\n(단위 : %)\n계열회사명\n사업자등록번호\n투 \xa0자 \xa0자\n서 정 진\n(주)셀트리온\n(주)셀트리온홀딩스\n(주)셀트리온헬스케어\n(주)셀트리온스킨큐어\n(주)셀트리온제약\n티에스이엔씨\n계\n(주)셀트리온\n133-81-23603\n-\n-\n19.75\n-\n2.13\n-\n-\n21.49\n(주)셀트리온홀딩스\n131-86-24858\n96.99\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n93.86\n(주)셀트리온헬스케어\n123-81-53473\n36.01\n\xa0-\n\xa0-\n\xa0-\n1.40\n\xa0-\n\xa0-\n44.12\n(주)셀트리온스킨큐어\n105-86-13560\n69.66\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n69.66\n셀트리온 유럽\n-\n\xa0-\n\xa0 \xa0 \xa0 \xa0100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n-\n100.00\n셀트리온 돈\n-\n\xa0-\n\xa0 \xa0 \xa0 \xa0100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n100.00\n셀트리온 예브라지아\xa0\n-\n\xa0-\n\xa0 \xa0 \xa0 \xa0100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n100.00\n(주)셀트리온제약\n214-86-71641\n\xa0-\n55.21\n-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n55.29\n(주)셀트리온엔터테인먼트\n107-87-63802\n\xa0-\n\xa0-\n100.00\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n100.00\n(주)셀트리온화학연구소\n135-81-52064\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0 \xa0 \xa0 \xa0100.00\n\xa0-\n100.00\n셀트리온팜유에스에이\r\n-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0 \xa0 \xa0 \xa0100.00\n\xa0-\n100.00\n티에스이엔엠\n113-81-82345\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n\xa0-\n60.00\n60.00\n타법인출자 현황\n(기준일 :\xa0\n2017년 12월 31일\n)\n(단위 : 천원, 주, %)\n법인명\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nA&G Pharmaceutical, Inc.\n2006.07.14\n신약개발투자\n2,676,548\n987,889\n16.51\n116,349\n-\n-\n-\n987,889\n16.51\n116,349\n3,138,322\n-236,900\n셀트리온 유럽\n2009.07.21\n유럽임상관련투자\n2\n1\n100.00\n2\n-\n-\n-\n1\n100.00\n2\n-\n-\n바이오톡스텍\n2009.07.28\n투자수익\n2,025,000\n1,631,134\n11.31\n9,215,907\n-\n-\n2,234,654\n1,631,134\n11.24\n11,450,561\n53,934,065\n1,475,312\n보스톤 인큐베이션투자조합\n2009.11.27\n투자수익\n2,500,000\n11\n25.00\n198,111\n-1\n-\n-55,000\n10\n25.00\n143,111\n1,150,586\n87,126\n셀트리온 예브라지아\n2009.12.09\n사업다각화\n392\n-\n100.00\n392\n-\n-\n-\n-\n100.00\n392\n-\n-\n셀트리온 돈\n2009.12.09\n사업다각화\n3,239,218\n-\n100.00\n-\n-\n-\n-\n-\n100.00\n-\n3,145,086\n-343,870\n제이티비씨\n2017.09.20\n투자수익\n500,000\n-\n0.09\n-\n100,000\n500,000\n-\n100,000\n0.09\n500,000\n203,739,476\n1,921,672\n프리미어 글로벌이노베이션 1호\n2017.06.15\n유망 바이오 벤처기업투자\n250,000\n-\n6.67\n-\n610\n610,000\n-\n610\n6.67\n610,000\n8,915,914\n-803,486\n매일방송\n2011.03.17\n투자수익\n1,000,000\n250,981\n0.45\n1,475,167\n-\n-\n-\n250,981\n0.45\n1,475,167\n414,636,801\n11,053,005\n뉴스1\n2011.06.09\n투자수익\n500,000\n60,000\n5.00\n202,251\n-\n-\n-\n60,000\n5.00\n202,251\n12,792,231\n2,082,832\n셀트리온제약\n2013.04.23\n경영참가 등\n50,057,259\n17,502,282\n55.29\n255,342,176\n875,114\n-\n-\n18,377,396\n55.12\n255,342,176\n469,195,117\n\xa015,778,955\n2014 성장사다리-IMM벤처펀드\n2014.08.11\n투자수익\n2,000,000\n6,077\n20.00\n6,076,600\n-964\n-963,200\n-\n5,113\n20.00\n5,113,400\n24,696,355\n15,133,089\n셀트리온에스티\n2016.04.01\n핵심정보 보안강화\xa0\n500,000\n100,000\n100.00\n500,000\n-100,000\n-\n-500,000\n-\n-\n-\n-\n-\n미래에셋셀트리온신성장투자조합 1호\n2017.03.31\n유망 바이오 벤처기업투자\n6,250,000\n-\n-\n-\n125\n12,500,000\n-\n125\n50.00\n12,500,000\n24,298,669\n-1,080,153\n합 계\n20,538,375\n\u3000\n273,126,955\n874,884\n12,646,800\n1,679,654\n21,413,259\n\u3000\n287,453,409\n1,270,613,929\n26,547,242\n']"
